Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8789945 | Urologic Oncology: Seminars and Original Investigations | 2018 | 11 Pages |
Abstract
Based on these results, bTURB is as safe and effective as mTURB in treatment of primary NMIBC. bTURB seems to have no evident advantages over mTURB with respect to operation time, perioperative and postoperative complication rates, and recurrence rates at 12 months.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Esmee I.M.L. M.D., Michael M.D., Eddie S.Y. M.D., Yoshiyuki M.D., Petrisor M.D., Young D. M.D., Theo M. M.D., Yasser M.D., Brant A. M.D., Jean J.M.C.H. M.D., Seiji M.D.,